Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Joan Fledelius

Showing results (1-10 of 24) with videos related to

Pageof 3
Sort By:
Seminars in Nuclear Medicine|March 7, 2025
Optimizing CT Imaging Parameters: Implications for Diagnostic Accuracy in Nuclear MedicineAnders F S Mikkelsen, Jesper Thygesen, Joan Fledelius
EJNMMI Research|September 23, 2016
Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapyJoan Fledelius, Azza Khalil, Karin Hjorthaug, et al.
Journal of Medical Imaging and Radiation Oncology|December 19, 2015
Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC)Joan Fledelius, Azza Ahmed Khalil, Karin Hjorthaug, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinibAnne Winther-Larsen, Joan Fledelius, Boe Sandahl Sorensen, et al.
European Clinical Respiratory Journal|March 12, 2021
Rare nocardiosis in danish patient with diabetesCecilie Norup Thomsen, Søren Sperling, Joan Fledelius, et al.
Clinical Nuclear Medicine|August 5, 2022
FDG PET/CT in a Patient With Syphilis Suspected of Having Penile CancerJakob Kristian Jakobsen, Joanna Szumniak, Christina Stilling, et al.
Nuclear Medicine Communications|July 23, 2020
Inter- and intraobserver agreement in standard and ultra-fast single-photon emission computed tomography/computed tomography for the assessment of bone metastasesHelle D Zacho, Ramune Aleksyniene, June A Ejlersen, et al.
American Journal of Nuclear Medicine and Molecular Imaging|March 14, 2018
Assessment of very early response evaluation with <sup>18</sup>F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methodsJoan Fledelius, Anne Winther-Larsen, Azza A Khalil, et al.
Translational Oncology|November 7, 2016
Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC PatientsAnne Winther-Larsen, Joan Fledelius, Christina Demuth, et al.
EJNMMI Research|April 10, 2020
Added value of <sup>68</sup>Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous <sup>99m</sup>Tc bone scintigraphyHelle D Zacho, Søren Ravn, Ali Afshar-Oromieh, et al.
Pageof 3

Showing results (1-10 of 24) with videos related to

Sort By:
Pageof 3
Seminars in Nuclear Medicine|March 7, 2025
Optimizing CT Imaging Parameters: Implications for Diagnostic Accuracy in Nuclear MedicineAnders F S Mikkelsen, Jesper Thygesen, Joan Fledelius
EJNMMI Research|September 23, 2016
Inter-observer agreement improves with PERCIST 1.0 as opposed to qualitative evaluation in non-small cell lung cancer patients evaluated with F-18-FDG PET/CT early in the course of chemo-radiotherapyJoan Fledelius, Azza Khalil, Karin Hjorthaug, et al.
Journal of Medical Imaging and Radiation Oncology|December 19, 2015
Using positron emission tomography (PET) response criteria in solid tumours (PERCIST) 1.0 for evaluation of 2'-deoxy-2'-[18F] fluoro-D-glucose-PET/CT scans to predict survival early during treatment of locally advanced non-small cell lung cancer (NSCLC)Joan Fledelius, Azza Ahmed Khalil, Karin Hjorthaug, et al.
Lung Cancer (Amsterdam, Netherlands)|March 15, 2016
Metabolic tumor burden as marker of outcome in advanced EGFR wild-type NSCLC patients treated with erlotinibAnne Winther-Larsen, Joan Fledelius, Boe Sandahl Sorensen, et al.
European Clinical Respiratory Journal|March 12, 2021
Rare nocardiosis in danish patient with diabetesCecilie Norup Thomsen, Søren Sperling, Joan Fledelius, et al.
Clinical Nuclear Medicine|August 5, 2022
FDG PET/CT in a Patient With Syphilis Suspected of Having Penile CancerJakob Kristian Jakobsen, Joanna Szumniak, Christina Stilling, et al.
Nuclear Medicine Communications|July 23, 2020
Inter- and intraobserver agreement in standard and ultra-fast single-photon emission computed tomography/computed tomography for the assessment of bone metastasesHelle D Zacho, Ramune Aleksyniene, June A Ejlersen, et al.
American Journal of Nuclear Medicine and Molecular Imaging|March 14, 2018
Assessment of very early response evaluation with <sup>18</sup>F-FDG-PET/CT predicts survival in erlotinib treated NSCLC patients-A comparison of methodsJoan Fledelius, Anne Winther-Larsen, Azza A Khalil, et al.
Translational Oncology|November 7, 2016
Early Change in FDG-PET Signal and Plasma Cell-Free DNA Level Predicts Erlotinib Response in EGFR Wild-Type NSCLC PatientsAnne Winther-Larsen, Joan Fledelius, Christina Demuth, et al.
EJNMMI Research|April 10, 2020
Added value of <sup>68</sup>Ga-PSMA PET/CT for the detection of bone metastases in patients with newly diagnosed prostate cancer and a previous <sup>99m</sup>Tc bone scintigraphyHelle D Zacho, Søren Ravn, Ali Afshar-Oromieh, et al.
Pageof 3